Accrued Liabilities (Notes)

3 Months Ended

Mar. 31, 2024

Accrued Liabilities [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Accrued Liabilities and Other Long-Term Liabilities

    Accrued liabilities consist of the following (in thousands): 

	As of
	March 31, 2024		December 31, 2023
Salaries and benefits	$	56,118	$	52,250
Incentive compensation	25,123		37,992
Operating lease liability-ST	18,532		20,161
Accrued sales taxes	5,295		6,748
Restructuring accrual	5,923		3,568
Deferred revenue	32,752		31,640
Accrued other taxes	3,399		3,024
Accrued professional fees	2,736		2,803
Italy medical device payback provision	23,227		23,176
Legal accrual	2,309		1,874
Distribution fees	12,407		13,049
Warranties and returns	3,638		3,682
Field service corrective action(1)	22,641		30,281
Accrued freight	14,916		17,215
Foreign exchange contracts	1,983		2,590
Accrued audit fees	4,143		5,492
Defined benefit plan	3,394		2,575
Accrued interest	1,413		1,431
Other	7,947		8,664
	$	247,896	$	268,215

___________________________

(1)     Primarily includes field service corrective actions associated with certain products in connection with a 2021 Warning Letter received by Smiths Medical from the FDA following an inspection of Smiths Medical’s Oakdale, Minnesota Facility, see Note 18: Commitments and Contingencies for further detail.

Other long-term liabilities consist of the following (in thousands): 

	As of
	March 31, 2024		December 31, 2023
Operating lease liability-LT	$	49,546	$	52,972
Benefits	4,124		4,207
Accrued rent	781		841
Finance lease liability-LT	1,861		1,954
Deferred revenue	10,605		10,585
Field service corrective action(1)	32,173		26,056
Other	3,504		3,882
	$	102,594	$	100,497